Michael Morris, MD
@mjmorrismd.bsky.social
Medical Oncologist and Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center.
Reposted by Michael Morris, MD
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
October 24, 2025 at 12:24 PM
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
Reposted by Michael Morris, MD
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.
annalsofoncology.org
May 20, 2025 at 6:16 PM
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Reposted by Michael Morris, MD
Congratulations to MSK's Dr. Justin Jee and Dr. Nikolaus Schultz for being accepted into Round 2 of @statnews.com #STATMadness. Vote for the team “Cancer Big Data” now: www.statnews.com/feature/stat...
March 12, 2025 at 4:47 PM
Congratulations to MSK's Dr. Justin Jee and Dr. Nikolaus Schultz for being accepted into Round 2 of @statnews.com #STATMadness. Vote for the team “Cancer Big Data” now: www.statnews.com/feature/stat...
Reposted by Michael Morris, MD
Congratulations to MSK's Dr. Natasha Rekhtman and Dr. Charles Rudin for being accepted into Round 1 of @statnews.com #STATMadness. Vote for the team “New Lung Cancer Subtype” now: www.statnews.com/feature/stat...
March 10, 2025 at 3:49 PM
Congratulations to MSK's Dr. Natasha Rekhtman and Dr. Charles Rudin for being accepted into Round 1 of @statnews.com #STATMadness. Vote for the team “New Lung Cancer Subtype” now: www.statnews.com/feature/stat...
Reposted by Michael Morris, MD
Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore
www.appliedclinicaltrialsonline.com/view/fda-app...
www.appliedclinicaltrialsonline.com/view/fda-app...
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.
www.appliedclinicaltrialsonline.com
March 29, 2025 at 7:19 AM
Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore
www.appliedclinicaltrialsonline.com/view/fda-app...
www.appliedclinicaltrialsonline.com/view/fda-app...
Reposted by Michael Morris, MD
Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP). #GU25
@charlesryanmd.bsky.social @mjmorrismd.bsky.social @ascopost.bsky.social meetings.asco.org/abstracts-pr...
@charlesryanmd.bsky.social @mjmorrismd.bsky.social @ascopost.bsky.social meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
February 14, 2025 at 5:06 AM
Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP). #GU25
@charlesryanmd.bsky.social @mjmorrismd.bsky.social @ascopost.bsky.social meetings.asco.org/abstracts-pr...
@charlesryanmd.bsky.social @mjmorrismd.bsky.social @ascopost.bsky.social meetings.asco.org/abstracts-pr...
So privileged to be among friends and colleagues for the second Feng symposium. Felix was friend and exemplar to us all.
February 12, 2025 at 9:08 PM
So privileged to be among friends and colleagues for the second Feng symposium. Felix was friend and exemplar to us all.
Reposted by Michael Morris, MD
American Society of Clinical Oncology (ASCO) provides advisory support for the association between alcohol & cancer. @ascocancer.bsky.social @ascopost.bsky.social
society.asco.org/news-initiat...
society.asco.org/news-initiat...
Oncology Society Urges Americans to Heed Surgeon General Advisory on Alcohol and Cancer
The U.S. Surgeon General’s office released a new advisory on the link between alcohol consumption and increased risk for cancer. The advisory reports alcohol use as the third leading preventable cause...
society.asco.org
January 5, 2025 at 4:44 PM
American Society of Clinical Oncology (ASCO) provides advisory support for the association between alcohol & cancer. @ascocancer.bsky.social @ascopost.bsky.social
society.asco.org/news-initiat...
society.asco.org/news-initiat...
Reposted by Michael Morris, MD
AMBASSADOR Trial: Adjuvant pembrolizumab improved disease-free survival in high-risk muscle-invasive urothelial carcinoma post-surgery (29.6 vs 14.2 months; HR 0.73). Grade ≥3 AEs: 50.6%.
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social
January 2, 2025 at 7:28 AM
AMBASSADOR Trial: Adjuvant pembrolizumab improved disease-free survival in high-risk muscle-invasive urothelial carcinoma post-surgery (29.6 vs 14.2 months; HR 0.73). Grade ≥3 AEs: 50.6%.
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social
Reposted by Michael Morris, MD
@thepcctc.bsky.social is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data Science, and Clinical Operations. For more info please visit www.linkedin.com/posts/prosta...
The Prostate Cancer Clinical Trials Consortium (PCCTC) on LinkedIn: PCCTC Data Management Internship, Remote in | Careers at Remote
The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data…
www.linkedin.com
December 24, 2024 at 6:53 PM
@thepcctc.bsky.social is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data Science, and Clinical Operations. For more info please visit www.linkedin.com/posts/prosta...
Nobody capture the holiday spirit more than @mskcancercenter.bsky.social facilities and engineering staff. Thanks for lifting our spirits with your decorations!
December 24, 2024 at 8:12 PM
Nobody capture the holiday spirit more than @mskcancercenter.bsky.social facilities and engineering staff. Thanks for lifting our spirits with your decorations!
Reposted by Michael Morris, MD
Heartbroken💔we lost Dr. Felix Feng— close friend, selfless collaborator, brilliant scientist. We miss you--too early my friend.
To all: please consider supporting this ACS/ASTRO award in Felix name:
donate.cancer.org/g/tjjfqwdnrxrl…?
To all: please consider supporting this ACS/ASTRO award in Felix name:
donate.cancer.org/g/tjjfqwdnrxrl…?
I just helped save a life
You can save one, too. Donate now.
https://donate.cancer.org/g/tjjfqwdnrxrl…
December 12, 2024 at 10:48 PM
Heartbroken💔we lost Dr. Felix Feng— close friend, selfless collaborator, brilliant scientist. We miss you--too early my friend.
To all: please consider supporting this ACS/ASTRO award in Felix name:
donate.cancer.org/g/tjjfqwdnrxrl…?
To all: please consider supporting this ACS/ASTRO award in Felix name:
donate.cancer.org/g/tjjfqwdnrxrl…?
Reposted by Michael Morris, MD
Telehealth Will Die In 3 Weeks Without Congressional Action www.forbes.com/sites/judyst...
Telehealth Will Die In 3 Weeks Without Congressional Action
Urgent action is needed to pass the Telehealth Modernization Act before it expires, ending telemedicine on Dec. 31. This would be devastating for disabled and rural patients.
www.forbes.com
December 10, 2024 at 4:43 AM
Telehealth Will Die In 3 Weeks Without Congressional Action www.forbes.com/sites/judyst...
A big thank you to the GU Oncologists and Nuc Meds of CTIC in Bogota, Colombia for their hospitality and scientific discussions. Great cancer center and #ProstateCancer care to be sure. Hope to work together in the future! Thanks to PCF for funding this scientific exchange.
December 10, 2024 at 6:09 PM
A big thank you to the GU Oncologists and Nuc Meds of CTIC in Bogota, Colombia for their hospitality and scientific discussions. Great cancer center and #ProstateCancer care to be sure. Hope to work together in the future! Thanks to PCF for funding this scientific exchange.
Just in time for Thanksgiving, nice pathology framework for characterizing treatment emergent neuroendocrine #ProstateCancer, a biologically diverse entity that everyone has a hard time describing, in CCR - thanks to Michael Haffner and @mishabeltran.bsky.social
aacrjournals.org/clincancerre...
aacrjournals.org/clincancerre...
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Abstract. Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine prostate cancer (NEPC) occurs in up to 15-20% of patients with castration-resistant prostate c...
aacrjournals.org
November 28, 2024 at 3:16 PM
Just in time for Thanksgiving, nice pathology framework for characterizing treatment emergent neuroendocrine #ProstateCancer, a biologically diverse entity that everyone has a hard time describing, in CCR - thanks to Michael Haffner and @mishabeltran.bsky.social
aacrjournals.org/clincancerre...
aacrjournals.org/clincancerre...
Reposted by Michael Morris, MD
Life could be a little bit hard for a junior scientist.
November 24, 2024 at 5:10 AM
Life could be a little bit hard for a junior scientist.
Reposted by Michael Morris, MD
Proud of my sister. Calm, deliberative, and forward focused. @blandro.bsky.social
youtube.com/watch?v=w2ft...
youtube.com/watch?v=w2ft...
youtube.com
November 24, 2024 at 1:33 AM
Proud of my sister. Calm, deliberative, and forward focused. @blandro.bsky.social
youtube.com/watch?v=w2ft...
youtube.com/watch?v=w2ft...
I remember my first-gen 128k Mac very fondly! Very musical drive noises...
#fbf
first test of a thrift store rescued Macintosh Performa 578 and it already has flying toasters installed 🥰
first test of a thrift store rescued Macintosh Performa 578 and it already has flying toasters installed 🥰
November 23, 2024 at 3:20 PM
I remember my first-gen 128k Mac very fondly! Very musical drive noises...
Thanks for the reminder! Really looking forward to the meeting this year.
ASCO annual meeting 2025 abstract submitter open - closes Jan 28th.
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
ASCO Meetings
conferences.asco.org
November 23, 2024 at 3:17 PM
Thanks for the reminder! Really looking forward to the meeting this year.
Reposted by Michael Morris, MD
Good write up of BlueSky #MedSky by @kristinafiore.bsky.social feat.
BlueSky elders:
@mdaware.org @gavinyamey.bsky.social @nickmark.bsky.social @kiswanson.bsky.social and @kidneyboy.bsky.social of course
www.medpagetoday.com/special-repo...
BlueSky elders:
@mdaware.org @gavinyamey.bsky.social @nickmark.bsky.social @kiswanson.bsky.social and @kidneyboy.bsky.social of course
www.medpagetoday.com/special-repo...
Physicians Flock to Bluesky, Hoping to Leave X Behind
Many compare it to the early days of Twitter
www.medpagetoday.com
November 20, 2024 at 12:03 PM
Good write up of BlueSky #MedSky by @kristinafiore.bsky.social feat.
BlueSky elders:
@mdaware.org @gavinyamey.bsky.social @nickmark.bsky.social @kiswanson.bsky.social and @kidneyboy.bsky.social of course
www.medpagetoday.com/special-repo...
BlueSky elders:
@mdaware.org @gavinyamey.bsky.social @nickmark.bsky.social @kiswanson.bsky.social and @kidneyboy.bsky.social of course
www.medpagetoday.com/special-repo...